Relmada Therapeutics Inc ( (RLMD) ) has released its Q3 earnings. Here is a breakdown of the information Relmada Therapeutics Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for neurological and psychological disorders, with its primary operations in the pharmaceutical industry. The company is known for its work on novel therapies such as NDV-01 and Sepranolone, targeting conditions like non-muscle invasive bladder cancer and Prader-Willi Syndrome, respectively.
In its latest earnings report for the quarter ended September 30, 2025, Relmada Therapeutics Inc. highlighted significant financial challenges, reporting a net loss of $10.1 million for the quarter and $37.5 million for the nine months ended September 30, 2025. The company’s cash and cash equivalents decreased significantly, reflecting ongoing operational expenses and strategic investments in its development pipeline.
Key financial metrics indicate a reduction in operating expenses compared to the previous year, with research and development expenses dropping from $11.1 million to $4 million for the quarter. Despite these reductions, the company continues to face substantial losses, primarily driven by its commitment to advancing clinical trials and strategic acquisitions, such as the purchase of Sepranolone from Asarina Pharma AB.
Looking forward, Relmada Therapeutics Inc. has taken steps to strengthen its financial position, including a recent underwritten offering that raised approximately $94 million. This capital infusion is expected to support the company’s operations and development activities for at least the next 12 months. Management remains focused on advancing its clinical programs and exploring strategic partnerships to enhance its pipeline and drive future growth.